At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKRO Akero Therapeutics
Post-Market Trading 12-24 13:49:43 EST
28.56
+0.19
+0.67%
盘后28.30
-0.26-0.91%
13:05 EST
High28.79
Low28.03
Vol266.38K
Open28.40
D1 Closing28.37
Amplitude2.68%
Mkt Cap1.99B
Tradable Cap1.57B
Total Shares69.80M
T/O7.60M
T/O Rate0.49%
Tradable Shares54.91M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?
Shares of Some Liver Disease Drugmakers Rise Between 2% and 11% ; Late-Stage Data From Novo's Weight-Loss Drug Shows Improvement in Fatty Liver Disease
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.